At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...
Merck (MRK) and Eisai (ESALF) announced on Tuesday that a late-stage trial evaluating two combination regimens involving the U.S. pharma giant's anti-PD1 inhibitor Keytruda failed to reach the main ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results